News

Advocate reacts to Texas governor signing psychedelic research bill into law

An advocate featured by KXAN celebrates Texas’s new legislation as a turning point—allocating $50 million in public funding for ibogaine clinical trials to address PTSD, addiction, and brain injury. She highlights the significance of this support for veterans and first responders.

Why Veterans With PTSD Are Turning to Psychedelics

Veterans are increasingly exploring psychedelic treatments—like ketamine, ayahuasca, psilocybin, MDMA, and ibogaine—to heal from PTSD. These therapies tend to be used in guided, clinically-informed settings, with some programs even including spouses for shared healing. Although ibogaine remains illegal in the U.S., many veterans are traveling abroad, driven by promising early results

‘Psychedelics and the Texas Trip’ explores science & history behind state-funded research initiative

Texas recently approved $50 million in public funding, matched privately, to study ibogaine—a plant-derived psychedelic—as a potential treatment for PTSD, TBI, addiction, and related conditions. The initiative is facilitated through a public–private partnership and includes protections to ensure future therapy revenues fund veterans’ programs

Texas passes nation’s first ibogaine research funding bill; Colorado’s first Natural Medicine client; and Psilocybin’s effects wane a year after dosing

Texas is the first state to fund clinical trials of ibogaine, investing $50 million in public funds to explore its potential for treating PTSD, addiction, and TBI—with future revenues supporting veterans’ programs.

Texas governor signs bill allocating up to $100 million in funding for psychedelics research

Texas has passed a landmark bill dedicating up to $100 million—half from public funds—to study ibogaine for conditions like PTSD, TBI, and addiction. A portion of future revenue will directly support veterans’ programs, marking a major step toward expanding access to psychedelic-assisted therapies.

Los Angeles Times: California Veterans Fight to Fast-Track Study of ‘Lifesaving’ Psychedelic Therapy

Veterans Exploring Treatment Solutions (VETS) Takes Center Stage at Psychedelic Science 2025

Veterans Exploring Treatment Solutions (VETS) brought its mission to the forefront at Psychedelic Science 2025, spotlighting the urgent need for access, equity, and innovation in veteran mental health. From policy advocacy to powerful storytelling, VETS delivered a bold message: healing is a right—and veterans deserve the freedom to pursue it.

Advocate reacts to Texas governor signing psychedelic research bill into law

Texas has taken a historic step toward advancing psychedelic science and veteran mental health. With the signing of SB 2308, the state will invest $50 million into ibogaine research—opening the door for FDA-approved studies on a treatment veterans have long sought abroad. As VETS continues advocating for clinical access to promising therapies, this milestone positions Texas at the forefront of evidence-based innovation for PTSD, TBI, and addiction.

How the Legacy of the “Bonus Army” Inspired a Modern Protest Movement of Military Veterans

Nearly a century after the original Bonus Army marched on Washington, veterans are once again mobilizing—this time to defend federal jobs, safeguard VA services, and demand dignity. On June 6, the “Bonus Army of 2025” returns to the Capitol, continuing a legacy of veteran-led advocacy. Among them are voices from VETS, helping elevate the call for respect, accountability, and access to the care veterans have earned.

NC lawmakers call for new look at psychedelic drugs for mental health therapy

Bipartisan momentum is building in North Carolina as lawmakers propose a new task force to explore the clinical use of psychedelic-assisted therapies for mental health. Backed by veterans, advocates, and legislators across the aisle, Senate Bill 568 signals a growing recognition of the urgent need for innovative solutions to the mental health crisis.